NVO — Novo Nordisk A/S
$39.05-0.96%
Last close: · regular session
After-hours $39.01 -0.10% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NVO in the TickerWise workspace.
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: DK
- Exchange: New York Stock Exchange
- Employees: 77,406
- Website: https://www.novonordisk.com
Latest SEC filings for NVO
Latest NVO news
- NVO vs. VKTX: Which Obesity Stock Could Deliver Bigger Gains? Read article
- Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility Read article
- Where Will Novo Stock Be in 10 Years? Read article
- How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results? Read article
- Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? Read article
- Novo's CagriSema leads to 25% weight loss in women Read article
- Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why Read article
- Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.